Congratulations to our Chief Medical Officer Dr Larry C Lands, for his unwavering dedication to ensuring that no Cystic Fibrosis (CF) patient is left behind. His efforts have been recognized with a prestigious grant from Génome Québec and Cystic Fibrosis Canada / Fibrose kystique Canada to advance a novel genetic therapy for individuals whose CF mutations do not respond to existing CFTR modulators. This groundbreaking project will harness prime editing, a cutting-edge gene modification technique, to permanently correct CFTR mutations.?We are fortunate to have Larry on the team at CILA, as we look to transform pulmonary healthcare with innovative solutions, technologies and therapies that measurably enhance patient outcomes.
Thank you Génome Québec and Cystic Fibrosis Canada / Fibrose kystique Canada for supporting our exciting project to formulate inhalable and intravenously-delivered lipid nanoparticles for the delivery of Prime Editing components to correct the DNA defect in Cystic Fibrosis. For those whose Cystic Fibrosis mutations do not respond to modulator therapy, projects like ours offer hope. I am very excited to co-lead this project with Jacques P. Tremblay, and work with Danuta Radzioch and the other project members. We will initially focus on the G542X mutation, with plans to extend to other non-responsive mutations. https://lnkd.in/eRvgnyw4